Nasdaq

Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin

Dexcom sponsored CONNECT randomized controlled trial expected to help establish new standard of care for CGM use by people with Type 2 diabetes not using insulin around the world. Showed use of Dexcom ...

DexCom Reports Positive CONNECT Data for Non-Insulin Diabetes

DXCM reports positive CONNECT trial results as Dexcom G7 improves HbA1c and time in range in adults with Type 2 diabetes not using insulin.

Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes

Dexcom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today that Health Canada has authorized the ...
Zacks Investment Research on MSN

DXCM secures Health Canada authorization for Dexcom G7 15 day CGM

DexCom DXCM recently announced that the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System has received ...

ADA26: Dexcom’s G7 CGM helps TD2 diabetics not on insulin manage glucose levels

Dexcom anticipates that the findings could drive a shift in the standard of care for type 2 diabetes patients who do not use ...
Hosted on MSN

Dexcom's glucose monitor use shows benefit in non-insulin diabetic patients in study

June 6 (Reuters) - Medical device maker Dexcom said the use of its continuous glucose monitor, G7, led to improved blood sugar control in patients with type 2 diabetes not using insulin, compared with ...

Dexcom alerts users after faulty G7 glucose sensors stolen and resold

Users can go to dexcom.com/theft-check for information on how to determine if sensors are from the affected lots and what action to take. Users also can call Dexcom Customer Support in the United ...